Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial,
Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
Amit K. Behera, Manoj Kumar, Muthu K. Shanmugam, Aditya Bhattacharya, Vinay J. Rao, Akshay Bhat, Madavan Vasudevan, Kodaganur S. Gopinath, Azeem Mohiyuddin, Anupam Chatterjee, Gautam Sethi, Tapas K. Kundu
Published Jun 4, 2019 · Vol. 10, No. 38 · pp. 3709-3724
Nicole E. James, Lindsey Beffa, Matthew T. Oliver, Ashley D. Borgstadt, Jenna B. Emerson, Clinton O. Chichester, Naohiro Yano, Richard N. Freiman, Paul A. DiSilvestro, Jennifer R. Ribeiro
Published May 21, 2019 · Vol. 10, No. 36 · pp. 3315-3327
Jessie Thalmensi, Elodie Pliquet, Christelle Liard, Gabriel Chamel, Christine Kreuz, Thomas Bestetti, Marie Escande, Anna Kostrzak, Anne-Sophie Pailhes-Jimenez, Emmanuèle Bourges, Marion Julithe, Ludovic Bourre, Olivier Keravel, Pascal Clayette, Thierry Huet, Simon Wain-Hobson, Pierre Langlade-Demoyen
Published May 21, 2019 · Vol. 10, No. 36 · pp. 3361-3372
Keywords: DNA vaccine, canine TERT, cancer, immunotherapy, Electro-Gene-Transfer
Stefano Guadagni, Giammaria Fiorentini, Andrea Mambrini, Francesco Masedu, Marco Valenti, Andrew Reay Mackay, Donatella Sarti, Enrico Ricevuto, Marco Clementi, Marco Catarci, Gianni Lazzarin, Gemma Bruera
Published May 14, 2019
Keywords: hypoxic pelvic perfusion with mitomycin C and oxaliplatin, unresectable recurrent rectal cancer, retrospective cohort study